These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 13285510)

  • 21. [The poison law; revision proposed by Medicinalstyrelsen].
    Sven Farm Tidskr; 1952 Dec; 56(34):712-5. PubMed ID: 13049084
    [No Abstract]   [Full Text] [Related]  

  • 22. [The Decree of 7 April 1960 on the manufacture, distribution and sale of pharmaceutical products].
    MARTELLIERE E
    Prod Pharm; 1960 Aug; 15():366-73 concl. PubMed ID: 13767280
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Food and Drug Administration; our mutual responsibility.
    HOLLAND AH
    N Y State J Med; 1955 Aug; 55(16):2327-30. PubMed ID: 13244856
    [No Abstract]   [Full Text] [Related]  

  • 25. Statement on H.R. 6471 on behalf of the Pharmaceutical Manufacturers Association.
    KLUMPP TG
    New Physician; 1962 Mar; 11():A74-A77. PubMed ID: 14457164
    [No Abstract]   [Full Text] [Related]  

  • 26. [Decree of May 30, 1960, bearing on the application of Article 603 of the Public Health Code establishing special patents for drugs].
    MARTELLIERE E
    Prod Pharm; 1960 Nov; 15():547-55. PubMed ID: 13767277
    [No Abstract]   [Full Text] [Related]  

  • 27. Patent wars: affordable medicines versus intellectual property rights.
    Wise J
    BMJ; 2014 Feb; 348():g1533. PubMed ID: 24535664
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 30. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 31. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
    Stephenson T
    Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supplements to new drug applications.
    MEYERS EL
    Bull Parenter Drug Assoc; 1962; 16():5-11. PubMed ID: 14473200
    [No Abstract]   [Full Text] [Related]  

  • 34. Significant developments in Federal drug controls.
    KESSENICH WH
    Mil Med; 1962 Mar; 127():259-65. PubMed ID: 14455401
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality assurance in proprietary medicines.
    Clarke CL
    Med Serv J Can; 1967 Mar; 23(3):277-86. PubMed ID: 6056373
    [No Abstract]   [Full Text] [Related]  

  • 36. Package inserts for prescription products.
    TICE LF
    Am J Pharm Sci Support Public Health; 1961 Jul; 133():240-2. PubMed ID: 13921160
    [No Abstract]   [Full Text] [Related]  

  • 37. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 38. [Charter of medicines promotion and rational use by physicians].
    Baumevieille M; Bégaud B; Maurain C
    Therapie; 2007; 62(1):39-44. PubMed ID: 17374346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bartole-Lucifredi bill, and that of the High Commission for Sanitation and Health, for control of pharmaceutical production].
    GROPPALI F
    Farmaco Prat; 1954 Jan; 9(1):8-41. PubMed ID: 13151201
    [No Abstract]   [Full Text] [Related]  

  • 40. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
    Shah S; Silva MA; Malloy MJ
    Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.